Watch Demo

New Zealand Antidiabetics Industry Outlook 2024 - 2028

See how New Zealand Antidiabetics performed compared to key markets such as Canada, Italy and Australia.

Key Market Indicators

New Zealander sales of diabetes medicine are projected to soar to approximately $175 million by 2028, up from roughly $94 million in 2023. This represents a robust annual growth rate of 9.6%. Since 1998, the New Zealand market has experienced a significant year-on-year increase of 18.9%. In 2023, New Zealand was ranked eighth globally, with Slovakia slightly ahead at the same $94 million mark. Italy, Australia, and Croatia hold the second, third, and fourth spots, respectively. In terms of insulin imports, New Zealand is set to reach about $25 million by 2028, growing from $22 million in 2023. This marks an annual growth rate of 1.9%. Since 1994, the country's insulin demand has seen a steady rise of 3.3% annually. New Zealand's insulin exports are also on the rise, expected to hit close to $381,000 by 2028, up from around $340,000 in 2023. This indicates an average yearly growth rate of 1.7%. Since 1994, New Zealand's insulin supply has increased by 4.1% each year. In 2023, New Zealand ranked 29th globally in insulin exports, with Slovenia surpassing them with the same $340,000 figure. France, Italy, and China occupy the second, third, and fourth positions in this ranking.

Marketing Banner

New Zealand Antidiabetics Market Data and Forecasts

How much will New Zealand Antidiabetics Market grow to 2028?

Forecast: Insulin in Dosage Market Size Value in New Zealand
Forecast: Import of Insulin in Dosage Forms to New Zealand
Forecast: Export of Insulin in Dosage Forms from New Zealand
Forecast: Re-Export of Insulin in Dosage Forms from New Zealand
Forecast: Import of Insulin in Dosage Forms to New Zealand
More in Antidiabetics Industry for 2028